Fawzi Abu Rous, Medical Oncologist at Henry Ford Health, shared a post on LinkedIn about a paper he co-authored with colleagues, published in the Journal of Clinical Oncology:
“Glad to have participated in the FRONT-BRAF study comparing immunotherapy w/wo chemo to BRAF/MEK inhibitors in 1st line treatment of BRAF-mut NSCLC. This is a highly relevant paper that can have immediate implications in the clinic!
Huge thanks to Biagio Ricciuti and Alessandro Di Federico for leading this effort and congrats to all co-authors!”
Title: First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF
V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Authors: Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Lanyi N Chen, Francesca R Ogliari, Paul Stockhammer, Rajat Thawani, Shahm Raslan, Eleonora Gariazzo, Francesca Fusco, Grace M Hambelton, Fabrizio Citarella, David Meyer, Mihaela Aldea, Andrea De Giglio, Joao V Alessi, Federica Pecci, Francesco Gelsomino, Marcelo Carassa, Natalie I Vokes, Xinan Wang, Dario De Biase, Fawzi Abu Rous, Phurin Areesawangkit, Omar Elghawy, Alessio Cortellini, Giulio Metro, Roberta Ferrara, Mark M Awad, Aliyah Pabani, Joseph C Murray, Federico Cappuzzo, Marina C Garassino, Ibiayi Dagogo-Jack, Gregory Kiely, Michael Grant, Benjamin O Herzberg, Andrea Ardizzoni, David Planchard, Bruce E Johnson, Corey J Langer, Michael Offin, Marcelo V Negraot, and Biagio Ricciuti.
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Fawzi Abu Rous.